Post-Launch In the post-launch phase, Xcenda recommends manufacturers conduct retrospective or prospective studies to understand the real-world impact of their product. Such studies can uncover new evidence to strengthen or refine the product's clinical and economic value proposition. And consistent research with payers and providers will forecast how policy changes or the availability of new, competitive therapies could impact coverage and utilization. Maximize commercial opportunities with the following key services: Conduct retrospective studiesGenerate evidence to prove clinical outcomes and utilization patterns through compliance and adherence assessments or economic resource utilization analyses.Read MoreBuild an outcomes analyzerGive payers a user-friendly software tool to understand patient treatment patterns, identify at-risk populations, and/or analyze healthcare resource consumption within their own patient population.Read MoreDevelop quality improvement programsFor high-cost treatments or those with heavily genericized indications, HEOR studies within specific patient populations deliver the comparative evidence required to support a product's refined value proposition.Read MoreCreate economic modelsDon't make price a barrier to patient access. Build effective account manager tools that demonstrate budget impact, cost-effectiveness, or disease burden.Read More Post-Launch: Additional ServicesExpand AllCollapse AllComparative Effectiveness ResearchMoreComparative Effectiveness Research When head-to-head clinical evidence is limited, use systematic reviews, retrospective claims analyses, and meta-analyses to establish comparative evidence to defend your market position as new treatments become available. Prospective studiesMoreProspective studies Generate scientifically sound patient-reported outcomes to more fully establish the economic and clinical value of your product.EpidemiologyMoreEpidemiology Retrospectively and prospectively capture safety and effectiveness data for treatments and interventions of interest. Use national and regional adverse events data to evaluate the prevalence of events and outcomes that may not have been detectable in clinical trials.Stakeholder insightsMoreStakeholder insights Continue to gather payer, provider, and patient insights to inform post-launch commercial strategies. Assess how payers react to new, real-world data, forecast how prescribing habits are changing in light of new therapeutic alternatives, or test how patients are responding to adherence programs.Risk managementMoreRisk management Monitor known risks, identify new potential risks, and study how contraindicated prescribing can influence your product’s evolving safety profile. Assess the impact of safety programs on patients, providers, and payers, and apply their insights to make programs more effective.Global Value DossiersMoreGlobal Value Dossiers Your dossier is an invaluable tool, an evolving repository of your product's clinical and economic value evidence. Is it time for an update?TrainingMoreTraining Increase your team's knowledge and effectiveness with training. From therapeutic topics to health outcomes to field reimbursement support, Xcenda's multidisciplinary experts customize each curriculum to meet each client's objectives, timeline, and budget.Health policy analysesMoreHealth policy analyses Closely track Congressional and regulatory health policy, including adjustments to Medicare and Medicaid, to anticipate how changes will impact the reimbursement landscape for your product.CompendiaMoreCompendia Monitor compendia for new, updated, and changed listings. Evaluate listings for your products and others within relevant disease states. Compare the compendia listings to what payers are covering and evaluate the effectiveness of your compendium strategy.PAP strategyMorePAP strategy Give your programs a check-up to ensure they remain effective. How can you maximize the number of patients supported while controlling costs? Should you adjust program benefit design elements, such as income eligibility criteria or patient-spend requirements? Do providers perceive your programs as "best in class"?Payer strategy and toolsMorePayer strategy and tools The need to identify, demonstrate, and communicate a product's clinical and economic value doesn't stop at launch. Develop effective payer strategies and tools to optimize coverage and reimbursement when competitors threaten.Value diagnosticMoreValue diagnostic Apply findings from retrospective or prospective studies to identify new value messages that reinforce why your product is superior to competitors. Leverage the findings of a market value framework to position your therapy so payers maximize coverage, even in a crowded therapeutic class.Contract HEOR staffMoreContract HEOR staff Are your payer field teams demanding HEOR tools to combat competitive threats? Do you need more manpower to support HEOR strategies for products already on the market and those still in development? Supplement your team of HEOR experts with ours, who are available via flexible contract staffing.Contract field reimbursement specialistsMoreContract field reimbursement specialists The market landscape is always changing. Even if product uptake at launch was strong, how might competitors or policy changes create new challenges? Or is your product's growth currently hampered by reimbursement challenges? Ensure patients who need your products can get them efficiently by continuing to offer providers the field reimbursement support they need to overcome barriers to access.Provider educationMoreProvider education Equip your sales force with a legally compliant resource proven to increase access to physicians. Help providers and staff translate reimbursement requirements, federal and state policy, coding, and coverage into understandable language and procedures that support appropriate patient access.